Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 2/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 10/20 | 0.43 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2671341 | 0.64 | MAPK14 (0.59) | AKT1MAPK14NPC1ALDH1A1 | |
| SCHEMBL31574295 | 0.64 | MAPK14 (0.46) | MAPK14BRD4 | |
| SCHEMBL21807461 | 0.64 | MAPK14 (0.46) | MAPK14BRD4 | |
| SCHEMBL5622730 | 0.63 | MAP2K1 (0.77) | MAP2K1ALDH1A1 | |
| SCHEMBL4077227 | 0.63 | MAPK14 (0.61) | MAPK14CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29376708 | 0.61 | MAPK14 (0.47) | AKT1MAPK14CYP2D6CYP2C19NPC1 | |
| SCHEMBL4144102 | 0.59 | MAPK14 (0.39) | MAPK14NPC1TSHRHSD17B10 | |
| SCHEMBL3805106 | 0.59 | MAP2K1 (0.47) | MAPK14MAP2K1BRD4ALDH1A1TSHR | |
| SCHEMBL17110585 | 0.59 | APP (0.55) | MAPK14CYP2D6CYP2C19NPC1ALDH1A1 | |
| SCHEMBL4430296 | 0.58 | PDE3B (0.39) | CYP2C19ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8080546-B2 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | AMGEN INC. (US) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137582-A1 | Pyrazolo-pyridinone derivatives and methods of use | IL1B, IL1R1, IL1A | AKT1 350/4885MAPK14 52/4885MAP2K1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.